Gold+
Booth No.Address | |||
---|---|---|---|
Telephone | +82-2-3484-0800 | Fax | |
Website | medinfoAPAC@takeda.com; so-youn.Lee@takeda.com |
Takeda Oncology, headquartered in Cambridge, Massachusetts, brings together our ever-expanding Global Oncology Business, R&D and Drug Discovery units into a single unified operation. Takeda Oncology’s proven commercialization capabilities allow us to quickly respond to the diverse and ever-changing needs of patients, healthcare providers and health systems around the world.
ALUNBRIG® (brigatinib) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). -ALUNBRIG Delivered High Response Rates and Durable Responses (ITT Population). The median DOR with ALUNBRIG was 33.1 months (95% CI: 22.0, NE). The median DOR was 13.8 months (95% CI: 10.4, 20.8) for crizotinib. -30.8 months PFS for ALUNBRIG vs 9.2 months for crizotinib (HR=0.43; 95% CI: 0.31, 0.61) -The Intracranial Response Rate Was 3 Times Higher With ALUNBRIG vs Crizotinib -Once-Daily Dosing Regimen That Fits Into Patients' Lives